Shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) were down 1.2% on Tuesday . The stock traded as low as $9.16 and last traded at $9.18, with a volume of 535,272 shares. The stock had previously closed at $9.29.

Several analysts recently commented on ACHN shares. Zacks Investment Research downgraded shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, April 27th. Leerink Swann reiterated a “market perform” rating and issued a $9.00 price target (up previously from $7.00) on shares of Achillion Pharmaceuticals in a research report on Wednesday, May 4th. Jefferies Group reiterated a “hold” rating on shares of Achillion Pharmaceuticals in a research report on Thursday, May 5th. Robert W. Baird reiterated an “outperform” rating and issued a $10.00 price target on shares of Achillion Pharmaceuticals in a research report on Monday, June 6th. Finally, JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $13.00 price target for the company in a research report on Thursday, July 7th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $9.63.

The stock has a market capitalization of $1.19 billion and a P/E ratio of 176.94. The company has a 50-day moving average price of $8.75 and a 200 day moving average price of $8.20.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.01. During the same period in the previous year, the firm posted ($0.25) EPS. Analysts expect that Achillion Pharmaceuticals Inc. will post ($0.63) earnings per share for the current year.

An institutional investor recently raised its position in Achillion Pharmaceuticals stock. Rhumbline Advisers raised its stake in shares of Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) by 14.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 117,525 shares of the biopharmaceutical company’s stock after buying an additional 14,425 shares during the period. Rhumbline Advisers owned about 0.09% of Achillion Pharmaceuticals worth $1,268,000 as of its most recent filing with the SEC.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.